PharmaShots | Incisive News in 3 Shots

Subscribe Now

UCB

UCB Reports Data of Bimekizumab in P-III (BE MOBILE 1) and (BE MOBILE 2) Studies for the Treatment of Axial Spondyloarthritis (axSpA) and Ankylosing Spondylitis (AS)

UCB Reports Data of Bimekizumab in P-III (BE MOBILE 1) and (BE MOBILE 2) Studies for the Treatment of Axial Spondyloarthritis (axS...

May 24, 2022

UCB Presents Efficacy and Safety Results of Zilucoplan and Rozanolixizumab in P-III (RAISE) & (MycarinG) Study for Generalized Myasthenia Gravis at MGFA 2022

UCB Presents Efficacy and Safety Results of Zilucoplan and Rozanolixizumab in P-III (RAISE) & (MycarinG) Study for Generalized Mya...

May 11, 2022

UCB Publishes Results of Fintepla (fenfluramine) in the P-III Trial for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in JAMA Neurology

UCB Publishes Results of Fintepla (fenfluramine) in the P-III Trial for the Treatment of Seizures Associated with Lennox-Gastaut S...

May 3, 2022

UCB’s Fintepla (fenfluramine) Receives the US FDA’s Approval for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB’s Fintepla (fenfluramine) Receives the US FDA’s Approval for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

March 29, 2022

UCB’s Bimzelx (bimekizumab) Receives Health Canada’s Approval for the Treatment of Plaque Psoriasis

UCB’s Bimzelx (bimekizumab) Receives Health Canada’s Approval for the Treatment of Plaque Psoriasis

February 18, 2022

UCB Signs a Definitive Agreement to Acquire Zogenix for ~$1.9B

UCB Signs a Definitive Agreement to Acquire Zogenix for ~$1.9B

January 19, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us